Cargando…
Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity
The blood–brain barrier (BBB) is a formidable obstacle to the delivery of therapeutics to the brain. Antibodies that bind transferrin receptor (TfR), which is enriched in brain endothelial cells, have been shown to cross the BBB and are being developed as fusion proteins to deliver therapeutic cargo...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175443/ https://www.ncbi.nlm.nih.gov/pubmed/29877588 http://dx.doi.org/10.1111/jnc.14482 |
_version_ | 1783361514013458432 |
---|---|
author | Haqqani, Arsalan S. Thom, George Burrell, Matthew Delaney, Christie E. Brunette, Eric Baumann, Ewa Sodja, Caroline Jezierski, Anna Webster, Carl Stanimirovic, Danica B. |
author_facet | Haqqani, Arsalan S. Thom, George Burrell, Matthew Delaney, Christie E. Brunette, Eric Baumann, Ewa Sodja, Caroline Jezierski, Anna Webster, Carl Stanimirovic, Danica B. |
author_sort | Haqqani, Arsalan S. |
collection | PubMed |
description | The blood–brain barrier (BBB) is a formidable obstacle to the delivery of therapeutics to the brain. Antibodies that bind transferrin receptor (TfR), which is enriched in brain endothelial cells, have been shown to cross the BBB and are being developed as fusion proteins to deliver therapeutic cargos to brain targets. Various antibodies have been developed for this purpose and their in vivo evaluation demonstrated that either low affinity or monovalent receptor binding re‐directs their transcellular trafficking away from lysosomal degradation and toward improved exocytosis on the abluminal side of the BBB. However, these studies have been performed with antibodies that recognize different TfR epitopes and have different binding characteristics, preventing inter‐study comparisons. In this study, the efficiency of transcytosis in vitro and intracellular trafficking in endosomal compartments were evaluated in an in vitro BBB model for affinity variants (K (d) from 5 to174 nM) of the rat TfR‐binding antibody, OX26. Distribution in subcellular fractions of the rat brain endothelial cells was determined using both targeted quantitative proteomics‐selected reaction monitoring and fluorescent imaging with markers of early‐ and late endosomes. The OX26 variants with affinities of 76 and 108 nM showed improved trancytosis (P(app) values) across the in vitro BBB model compared with a 5 nM OX26. Although ~40% of the 5 nM OX26 and ~35% of TfR co‐localized with late‐endosome/lysosome compartment, 76 and 108 nM affinity variants showed lower amounts in lysosomes and a predominant co‐localization with early endosome markers. The study links bivalent TfR antibody affinity to mechanisms of sorting and trafficking away from late endosomes and lysosomes, resulting in improvement in their transcytosis efficiency. OPEN PRACTICES: [Image: see text] Open Science: This manuscript was awarded with the Open Materials Badge. For more information see: https://cos.io/our-services/open-science-badges/ [Image: see text] Cover Image for this issue: doi: 10.1111/jnc.14193. |
format | Online Article Text |
id | pubmed-6175443 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61754432018-10-19 Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity Haqqani, Arsalan S. Thom, George Burrell, Matthew Delaney, Christie E. Brunette, Eric Baumann, Ewa Sodja, Caroline Jezierski, Anna Webster, Carl Stanimirovic, Danica B. J Neurochem ORIGINAL ARTICLES The blood–brain barrier (BBB) is a formidable obstacle to the delivery of therapeutics to the brain. Antibodies that bind transferrin receptor (TfR), which is enriched in brain endothelial cells, have been shown to cross the BBB and are being developed as fusion proteins to deliver therapeutic cargos to brain targets. Various antibodies have been developed for this purpose and their in vivo evaluation demonstrated that either low affinity or monovalent receptor binding re‐directs their transcellular trafficking away from lysosomal degradation and toward improved exocytosis on the abluminal side of the BBB. However, these studies have been performed with antibodies that recognize different TfR epitopes and have different binding characteristics, preventing inter‐study comparisons. In this study, the efficiency of transcytosis in vitro and intracellular trafficking in endosomal compartments were evaluated in an in vitro BBB model for affinity variants (K (d) from 5 to174 nM) of the rat TfR‐binding antibody, OX26. Distribution in subcellular fractions of the rat brain endothelial cells was determined using both targeted quantitative proteomics‐selected reaction monitoring and fluorescent imaging with markers of early‐ and late endosomes. The OX26 variants with affinities of 76 and 108 nM showed improved trancytosis (P(app) values) across the in vitro BBB model compared with a 5 nM OX26. Although ~40% of the 5 nM OX26 and ~35% of TfR co‐localized with late‐endosome/lysosome compartment, 76 and 108 nM affinity variants showed lower amounts in lysosomes and a predominant co‐localization with early endosome markers. The study links bivalent TfR antibody affinity to mechanisms of sorting and trafficking away from late endosomes and lysosomes, resulting in improvement in their transcytosis efficiency. OPEN PRACTICES: [Image: see text] Open Science: This manuscript was awarded with the Open Materials Badge. For more information see: https://cos.io/our-services/open-science-badges/ [Image: see text] Cover Image for this issue: doi: 10.1111/jnc.14193. John Wiley and Sons Inc. 2018-08-16 2018-09 /pmc/articles/PMC6175443/ /pubmed/29877588 http://dx.doi.org/10.1111/jnc.14482 Text en © 2018 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | ORIGINAL ARTICLES Haqqani, Arsalan S. Thom, George Burrell, Matthew Delaney, Christie E. Brunette, Eric Baumann, Ewa Sodja, Caroline Jezierski, Anna Webster, Carl Stanimirovic, Danica B. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity |
title | Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity |
title_full | Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity |
title_fullStr | Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity |
title_full_unstemmed | Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity |
title_short | Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood–brain barrier in vitro is dependent on its binding affinity |
title_sort | intracellular sorting and transcytosis of the rat transferrin receptor antibody ox26 across the blood–brain barrier in vitro is dependent on its binding affinity |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175443/ https://www.ncbi.nlm.nih.gov/pubmed/29877588 http://dx.doi.org/10.1111/jnc.14482 |
work_keys_str_mv | AT haqqaniarsalans intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT thomgeorge intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT burrellmatthew intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT delaneychristiee intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT brunetteeric intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT baumannewa intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT sodjacaroline intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT jezierskianna intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT webstercarl intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity AT stanimirovicdanicab intracellularsortingandtranscytosisoftherattransferrinreceptorantibodyox26acrossthebloodbrainbarrierinvitroisdependentonitsbindingaffinity |